Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Doxorubicin Changes the Spatial Organization of the Genome around Active Promoters

ABSTRACT: Doxorubicin Changes the Spatial Organization of the Genome around Active Promoters

PROVIDER: PRJNA889755 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR21875377.fastq.gz	Fastqsanger.gz
	SRR21875378.fastq.gz	Fastqsanger.gz
	SRR21875379.fastq.gz	Fastqsanger.gz
	SRR21875380.fastq.gz	Fastqsanger.gz
	SRR21875381.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 21

Similar Datasets

Doxorubicin Changes the Spatial Organization of the Genome around Active Promoters

Project description:Doxorubicin Changes the Spatial Organization of the Genome around Active Promoters

| PRJNA889762 | ENA

Doxorubicin Changes the Spatial Organization of the Genome around Active Promoters

Project description:Doxorubicin Changes the Spatial Organization of the Genome around Active Promoters

| PRJNA887734 | ENA

Doxorubicin Changes the Spatial Organization of the Genome around Active Promoters

Project description:Doxorubicin Changes the Spatial Organization of the Genome around Active Promoters

| PRJNA889765 | ENA

Doxorubicin Changes the Spatial Organization of the Genome around Active Promoters

Project description:To investigate the function of the doxorubicin treatment in differentiation expression of human genes, we performed gene expression profiling analysis using data obtained from RNA-seq of three different conditions: control (DMSO-treatment) and doxorubicin treatment (200 nM and 340 nM).

2023-03-31 | GSE215321 | GEO

Doxorubicin Changes the Spatial Organization of the Genome around Active Promoters

Project description:To investigate the function of the TOP2 inhibitors treatment in binding of chromatin architecture factors, we performed ChIP-seq. We used chromatin from RPE1 cells treated with four different conditions: control (DMSO-treatment), doxorubicin treatment (200 nM and 340 nM) and ICRF193 treatment (5uM).

2023-03-31 | GSE215318 | GEO

Doxorubicin enhances nucleosome turnover around promoters

Project description:We use a metabolic labeling strategy for directly measuring nucleosome turnover to examine the effect of doxorubicin on chromatin dynamics in squamous cell carcinoma cell lines derived from genetically defined mice. We find that doxorubicin enhances nucleosome turnover around gene promoters, and turnover correlates with gene expression level. Keywords: Chromatin affinity-purification on microarray 26 CATCH-IT arrays and 8 expression arrays.

2013-04-19 | E-GEOD-43753 | biostudies-arrayexpress

Doxorubicin enhances nucleosome turnover around promoters

2013-04-19 | GSE43753 | GEO

Doxorubicin Changes the Spatial Organization of the Genome around Active Promoters.

Project description:In this study, we delve into the impact of genotoxic anticancer drug treatment on the chromatin structure of human cells, with a particular focus on the effects of doxorubicin. Using Hi-C, ChIP-seq, and RNA-seq, we explore the changes in chromatin architecture brought about by doxorubicin and ICRF193. Our results indicate that physiologically relevant doses of doxorubicin lead to a local reduction in Hi-C interactions in certain genomic regions that contain active promoters, with changes in chromatin architecture occurring independently of Top2 inhibition, cell cycle arrest, and differential gene expression. Inside the regions with decreased interactions, we detected redistribution of RAD21 around the peaks of H3K27 acetylation. Our study also revealed a common structural pattern in the regions with altered architecture, characterized by two large domains separated from each other. Additionally, doxorubicin was found to increase CTCF binding in H3K27 acetylated regions. Furthermore, we discovered that Top2-dependent chemotherapy causes changes in the distance decay of Hi-C contacts, which are driven by direct and indirect inhibitors. Our proposed model suggests that doxorubicin-induced DSBs cause cohesin redistribution, which leads to increased insulation on actively transcribed TAD boundaries. Our findings underscore the significant impact of genotoxic anticancer treatment on the chromatin structure of the human genome.

| S-EPMC10417312 | biostudies-literature

Doxorubicin Changes the Spatial Organization of the Genome around Active Promoters

Project description:To investigate the function of TOP2 on chromatin structure of human cells, we performed Hi-C using chromatin obtained from RPE1 cells.

2023-03-31 | GSE214912 | GEO

Doxorubicin Changes the Spatial Organization of the Genome around Active Promoters

Project description:This SuperSeries is composed of the SubSeries listed below.

2023-03-31 | GSE215325 | GEO